source
- BMS CAR-T therapy arlo-cel meets primary endpoint in pivotal multiple myeloma trialBristol Myers Squibb reported that its GPRC5D-directed CAR-T cell therapy, arlo-cel, achieved the primary endpoint in the pivotal Quintessential trial for multiple myeloma. The study enrolled pati…
- Schrödinger launches Tectora Therapeutics with $55 million Series A to target immunology and inflammationSchrödinger announced the formation of Tectora Therapeutics, a new biotech focused on immune‑mediated diseases, backed by a $55 million Series A financing round. As part of the launch, Schrödinger…